Catalent, Inc. (CTLT)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

109.38+0.12 (+0.11%)

At close: 4:03PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	109.26
Open	108.50
Bid	107.27 x 800
Ask	111.76 x 900
Day's Range	107.99 - 109.79
52 Week Range	54.21 - 127.68
Volume	1,014,916
Avg. Volume	1,056,140

Market Cap	18.619B
Beta (5Y Monthly)	1.44
PE Ratio (TTM)	60.60
EPS (TTM)	1.80
Earnings Date	May 03, 2021 - May 07, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	133.90

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-28% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Insider Monkey
Is CTLT Stock A Buy or Sell?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of December 31st. The results of that effort will be put on display in this article, as […]
- How Much Are Preformed Line Products Company (NASDAQ:PLPC) Insiders Spending On Buying Shares?
  Simply Wall St.
- Did EchoStar Corporation (NASDAQ:SATS) Insiders Buy Up More Shares?
  Simply Wall St.
Zacks
Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine
Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.
- Northwestern hosts midnight vaccine clinic
  WLS – Chicago
- New Zealand's Ardern says border workers must take COVID-19 vaccine after new cases
  Reuters
Business Wire
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the expansion of their strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs in Moderna’s pipeline, at Catalent’s biologics facility in Bloomington, Indiana.